leadf
logo-loader
ASX:SUD

SUDA Pharmaceuticals Ltd

Receive alerts
Market:
ASX
Market Cap:
$25 m
Price
0.05 AUD
Change
0.00%
52 weeks high
0.08
52 weeks low
0.03

In brief

SUDA Pharmaceuticals Ltd (ASX:SUD) is focused on developing therapies to treat human disease.

The company's two main focus areas are oncology and conditions that impact the central nervous system.

SUDA is developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers, along with low-risk oral sprays to reformulate existing pharmaceuticals.

Snapshot

  • SUDA Pharmaceuticals appoints internationally recognised clinical immunologist to iNKT cell therapy Scientific Advisory Board
  • Suda Pharmaceuticals ends June quarter with $6.7 million in bank as it prepares to move forward its iNKT cell therapy platform licence
  • Suda Pharmaceuticals' introduce novel iNKT cell therapy platform from Imperial College London

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Suda Pharmaceuticals ends June quarter with $6.7 million in bank as it prepares to move forward its iNKT cell therapy platform licence

The biotechnology company released its fourth-quarter report, unveiling cash receipts for the quarter of $68,000 and net outflow of $909,000 from operating activities for the quarter.

on 26/7/21